Welcome to our dedicated page for Hepion Pharmaceuticals SEC filings (Ticker: CTRVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Hepion Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Hepion Pharmaceuticals's regulatory disclosures and financial reporting.
Hepion Pharmaceuticals director Appajosyula Sireesh bought 1,250,000 shares of common stock in an open-market transaction at $0.04 per share. Following this purchase on April 21, 2026, he holds 1,250,000 shares directly, indicating a newly established reported ownership position.
Hepion Pharmaceuticals interim CEO Gary S. Stetz reported an indirect open-market purchase of 1,250,000 shares of common stock at $0.04 per share. The shares are held through the Stetz Belgiovine CPA 401K F/B/O Gary S. Stetz account, and this filing shows total indirect holdings of 1,250,000 shares after the transaction.
Hepion Pharmaceuticals, Inc. entered into securities purchase agreements with accredited investors for a private placement of common stock. The company agreed to sell an aggregate of 17,500,000 shares of common stock at an offering price of $0.04 per share, for gross proceeds of $700,000.
The transaction closed on April 21, 2026. The shares were issued in an unregistered offering relying on exemptions under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, meaning they cannot be freely resold in the United States without registration or a valid exemption.
Hepion Pharmaceuticals, Inc. reported leadership changes and a separation package for its former chief executive. The company entered into a separation agreement with former CEO Dr. Kaouthar Lbiati effective April 13, 2026, following her earlier resignation for personal reasons.
Under this agreement, Dr. Lbiati will receive $225,000, a $30,625 payment representing the pro‑rated portion of her potential cash bonus, and reimbursement of her COBRA health insurance payments for six months. She also agreed to a general release and confidentiality provisions. On the same date, Dr. Lbiati resigned as a director of the company, leaving both her executive and board roles.
Hepion Pharmaceuticals, Inc. director and Chief Executive Officer Gary S. Stetz filed an initial statement of beneficial ownership on Form 3. The filing lists him as both a director and officer of the company but does not report any specific holdings or transactions in this excerpt.
Hepion Pharmaceuticals, Inc. filed an initial Form 3 identifying Vincent S. LoPriore as an insider. He is listed as both a director and an officer, serving as Executive Chairman. The filing does not report any share purchases, sales, or other insider transactions.
Hepion Pharmaceuticals, Inc. filed an initial ownership report for director Appajosyula Sireesh on Form 3. The filing shows no reportable transactions and no derivative positions, with all buy, sell, acquire, and dispose counts and related share amounts reported as zero.
Hepion Pharmaceuticals announced that Chief Executive Officer Dr. Kaouthar Lbiati resigned for personal reasons, effective immediately on March 16, 2026. The Board moved quickly to reconfigure leadership, naming Gary Stetz as interim CEO and a director the same day.
The Board also appointed Vincent LoPriore as Executive Chairman and added Sireesh Appajosyula and Chase LoPriore as directors. The company states there are no special arrangements behind these appointments and no family relationships between the new leaders and existing directors or executive officers.
Hepion Pharmaceuticals’ annual report outlines a major strategic shift and significant financial risk. The company has exited its prior focus on liver drug rencofilstat, winding down the ASCEND-NASH trial in 2024 and selling all rencofilstat-related assets to Panetta Partners in May 2025 for a nominal amount, with only contingent value rights retained for shareholders.
Hepion is repositioning as a medical diagnostics company, in-licensing CE‑marked tests for celiac disease, respiratory multiplex, H. pylori and hepatocellular carcinoma from New Day Diagnostics in May 2025, and liver disease diagnostic intellectual property from Cirna Diagnostics in February 2026. The New Day arrangement resulted in total consideration of $815,045, all expensed after impairment.
The company has an accumulated deficit of $246.1 million as of December 31, 2025, and discloses substantial doubt about its ability to continue as a going concern, expecting to exhaust available cash during the third quarter of 2026 without additional capital. It raised approximately $8.2 million in 2025 and $4.3 million in 2024 but now has only two employees and no internal manufacturing or commercial infrastructure, relying on third parties for development and future production.
Hepion Pharmaceuticals entered a material intellectual property license agreement with Cirna Diagnostics, adding a liver disease diagnostic asset to its portfolio. The company will pay an upfront $50,000, certain patent expenses, up to $2,350,000 in development milestones, up to $4,500,000 in sales milestones, and low single-digit royalties on net sales.
Hepion also highlighted a novel circulating tumor RNA biomarker assay for earlier diagnosis and surveillance of hepatocellular carcinoma in high-risk patients, reinforcing its strategic shift toward liquid biopsy-based cancer diagnostics under new leadership.